Linezolid Krka

Linezolid, the active ingredient in Linezolid Krka, is an oxazolidinone presented as an oral tablet for oral use. It treats infections caused by susceptible Gram‑positive bacteria, including skin and soft‑tissue infections and various forms of pneumonia, in adult patients. GNH USA supplies Linezolid Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linezolid is an oxazolidinone antibiotic indicated for several serious bacterial infections. - Skin and soft tissue infections: effective against susceptible Gram‑positive pathogens, reducing lesion size and systemic symptoms. - Community‑acquired bacterial pneumonia: provides coverage for resistant strains, improving respiratory function. - Nosocomial pneumonia: treats hospital‑acquired lung infections caused by resistant organisms. - Methicillin‑resistant Staphylococcus aureus (MRSA) infections: eradicates MRSA strains in various tissues. - Vancomycin‑resistant Enterococcus (VRE) infections: offers an alternative therapy for VRE‑related infections.

Linezolid may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: transient gastrointestinal discomfort. - Diarrhea: loose stools, often self‑limiting. - Headache: mild to moderate intensity. - Metallic taste: altered taste perception during therapy.

Serious or Rare Side Effects: - Thrombocytopenia: significant drop in platelet count requiring monitoring. - Peripheral neuropathy: nerve damage presenting as tingling or numbness. - Serotonin syndrome: risk when combined with serotonergic agents, causing agitation, hyperthermia, and autonomic instability.

Before initiating Linezolid therapy, consider the following safety measures. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution and observe liver enzymes. - Concomitant serotonergic drugs: avoid due to risk of serotonin syndrome. - Long‑term use: regularly assess complete blood counts for hematologic toxicity. - Pregnancy and lactation: safety unknown; prescribe only if benefits outweigh potential risks. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Linezolid can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs): may precipitate serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): increase risk of severe serotonin toxicity. - Rifampicin: induces metabolism, reducing linezolid plasma concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: may potentiate anticoagulant effect, necessitating INR monitoring. - Erythromycin: can elevate linezolid levels, increasing toxicity risk. - Anticonvulsants (e.g., carbamazepine): may lower linezolid exposure, reducing efficacy.